ÚLTIMAS NOVIDADES E EVENTOS

EANM position paper on the role of radiobiology in nuclear medicine

Aerts, A., Eberlein, U., Holm, S. et al. EANM position paper on the role of radiobiology in nuclear medicine. Eur J Nucl Med Mol...

ANZSNM 2021 Live and Local

Event: 51st Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM) Date: 21-23 May 2021 This meeting will be moving to...

Travel cards could help radiopharma patients avoid delays

April 29, 2020 -- Patients who undergo radiation treatment with lutetium-177 (Lu-177)-DOTATATE for neuroendocrine tumors should receive and carry a travel card with details of...

PSMA theranostic Lu-177-PSMA-617 approaches prime time in mCRPC

Urology Times Journal, Jason M. Broderick - April 15, 2021 The PSMA-targeted radiopharmaceutical 177Lu-PSMA-617 (LuPSMA) is rapidly advancing through the pipeline in metastatic castration-resistant prostate...

XXII Congreso Argentino de Medicina Nuclear – Virtual Edition

Event: XXII Congreso Argentino de Medicina Nuclear - Virtual Edition Date: 26-30 April 2021 The Oncidium foundation is proud to be represented by our Ambassadors to...

The Noble Registry – An International Collaboration to Develop iPSMA SPECT Imaging for Prostate Cancer

BRUSSELS, Belgium and MELBOURNE, Australia, 20th of April 2021 – The Oncidium foundation, a non-profit organisation created to promote and support the development of...

Doctor, What is Neuroendocrine Cancer?

Waiting for a download is frustrating. Imagine waiting 5+ years for a cancer diagnosis. Neuroendocrine cancer takes on average 5+ years to diagnose due...

How Nuclear Technology can Beat Cancer

How nuclear medicine can beat cancer? These are extraordinary times, and patients waiting for life-changing medical treatments should not suffer. They want to know...

Seeing Cancer Cells, Killing Cancer Cells

Using molecules to safely carry radioactive materials inside the human body is helping physicians get more accurate images of tumors and more effectively eliminate...

Evolving role of Ac-225-PSMA Radioligand Therapy in mCRPC

225Ac-PSMA RLT is an efficacious and safe treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). Future randomized controlled trials are required to...

World Theranostics Day 2021!

Today is World Theranostics Day! On this day in 1941, the first radioiodine treatment was administered and we are very eager to see what's...

How PRRT can Improve Care for Neuroendocrine Tumor Patients

Learn more about how Peptide Receptor Radionuclide Therapy (PRRT) can improve care for Neuroendocrine Tumor patients. Another effective illustration of how Radiotheranostics work and...

Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy

With some radiopharmaceuticals now used in clinical practice, somatostatin analogs developed for imaging and therapy are an example of the concept of personalized medicine...

Real-world data analysis of efficacy and survival after Lu-177 PSMA in metastatic castration-resistant prostate cancer

177Lu-PSMA radioligand therapy provides a significant response rate with a low toxicity profile. The evidence promotes greater efficacy of radioligand therapy in predominantly lymph...

PSMA Lu-177 x Ac-225

Available since 2015, the treatment of patients with metastatic castration-resistant prostate cancer (mCRPCC) with the beta-emitter Lutetium-177 has had several early-stage dosimetry studies published,...

What is in the pipeline for nuclear medicine, globally?

In recent years, the nuclear medicine market has undergone many changes. The medical specialty, not well known to the general public, is gaining more...

Oncidium foundation welcomes it’s Turkish Ambassador

Welcome Mr. Hasan Ulaş Özcan as an Oncidium foundation Ambassador in Turkey. Our mission is to support & promote the development of Radiotheranostics globally....

Oncidium foundation is a corporate member of the SNMMI Value Initiative

The Oncidium foundation is a corporate member of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Value Initiative program to advance the crucial...

Joint Radionuclide Therapy-Immunotherapy Approach Effective in Prostate Cancer Model

Joint radionuclide therapy and immunotherapy approach. The combination shows promising therapeutic option for prostate cancer patients. Read full article >>  

Winter Neswletter is out!

Looking back at 2020 accomplishments, fundraising campaign, meeting the newcomers Ambassadors, focusing on the latest developments in the Radiotheranostics field and meeting Tom, neuroendocrine...

World Cancer Day 2021

Today, the Oncidium foundation unites its voice with the World Cancer Day! No matter who we are or where we live, this occasion is...

Hopeful 2021!

This year has shown us more than ever the importance of access, education & hope. We've adapted to new normal & witnessed once again the...

New Theranostic Approach reduces tumor volume and increases survival in NET’s study

Axis - Dec 16, 2020   According to new research published in the December issue of The Journal of Nuclear Medicine, the imaging agent 64Cu-CuSarTate produced high-quality...

Another achievement to bring Radiotheranostics forward

300 hospitals registered on the Oncidium foundation Map! Another achievement to bring Radiotheranostics forward and strive for access education and hope. Thank you to...

NET Patient Testimonial, how PRRT saved Tom’s life

Tom is a composer, pianist, audio producer and neuroendocrine tumor patient. When he was diagnosed with NET's, he didn't know that PRRT could save his life...

Diagnostic accuracy of 18 F-PSMA-1007-PET/CT imaging for prostate carcinoma

J. Nucl. Me. 2020 Aug 17 18F-PSMA-1007-PET/CT reliably detects malignant lymph nodes and has an exceptional specificity of >99% for nodal metastases. Congratulations for this...

SNMICON 2019

Event: Oncidium Talk during SNMICOM Date: 14 December 2019 Time: 10.40-10.55 AM Location: Hall B, The Majestic The LaLit, Sahar Airport Rd, Mumbai, India

International Symposium Bad Berka 2019

Event: The Inauguration of the ICPO Foundation & The 20th Anniversary of Molecular Radiotherapy Date: 12-14 December 2019 Location: Zentralklinik, Bad Berka

This is not a simple flower, this is an Oncidium

Ever wondered the meaning behind the name and logo of the Oncidium foundation? This is not a flower, this is an Oncidium. A kind of...

IPET 2020 – all you need to know about Theranostics

Event: IPET 2020, Beyond the visible - International Conference on Molecular Imaging and Clinical PET-CT in the Era of Theranostics Date: 24-26 November 2020 Don't miss...

Radiopharmaceuticals Emerging as New Cancer Therapy

National cancer Institute. October 26, 2020 The last years have seen an explosion of research and clinical trials testing new radiopharmaceuticals suggesting that targeting radiation...

October Rose – Breast Cancer Awareness Month

The Oncidium foundation wears the colors of October Rose. Breast Cancer is by far the most common cancer in women worldwide, both in developed...

EANM ’20 – Let’s talk Radiotheranostics!

Event: EANM 2020 Annual Meeting - Virtual Edition Date: 22-30 October 2020 This year, the Oncidium foundation team looks forward to meeting you “virtually” at the EANM...

Nuclear Medicine and Molecular Imaging Week: October 4-10, 2020

October 4-10 2020 is nuclear medicine and molecular imaging week! A great initiative by Society of Nuclear Medicine and Molecular Imaging (SNMMI) to raise...

First clinical results for PSMA TAT using Ac-225-PSMA-I&T in advanced mCRPC patients

First clinical results for PSMA targeted alpha therapy using 225Ac-PSMA-I&T in advanced metastatic castration resistant prostate cancer patients: promising antitumor effect in advanced mCRPC...

IAEA activities on Cu-67, Re-186, Sc-47 Theranostic radionuclides and Radiopharmaceuticals

International Atomic Energy Agency (IAEA) activities on 67Cu, 186Re, 47Sc Theranostic radionuclides and Radiopharmaceuticals: Extraordinary results on the production, quality control and preclinical evaluation...

The Role of Ga-68-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience

The Role of 68Ga-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract (LGT): First Clinical Experience seems to be a highly promising...

Cancer awareness month – September, don’t forget to remember

The month of September represents the prostate cancer, thyroid cancer, leukemia and lymphoma, and female cancer awareness month. Thus, an important way of supporting...

First patients dosed in clinical trial of novel lung and ovarian cancer theranostic

Telix Pharmaceuticals Limited announced that the first two patients have been dosed in a phase I study of the novel lung and ovarian cancer...

Sirtex Medical and China Grand Pharmaceutical announce landmark drug registration milestone

Sirtex Medical (“Sirtex”) is a leading manufacturer of targeted liver cancer therapies. It announced today that Sirtex and its shareholders have been issued a...

Efficacy and safety of 225 Ac-PSMA-617 TAT in Prostate Cancer

PubMed, July 23, 2020 Despite the success of several standards of care treatment options in metastatic castration-resistant prostate cancer (mCRPC), a significant number of patients...

Astatine is a chemistry puzzle that shows anticancer promise

c&en, chemical & engineering news, august 13, 2020. Astatine is the rarest naturally occurring element on Earth. It resists easy chemical classification. In reactions, it...

Webinar Theranostics and PET Imaging Diagnostics

Webinar Theranostics and PET Imaging Diagnostics by IBA RadioPharma Solutions Watch this instructive webinar on the use of PET radiopharmaceuticals in Theranostic applications....

Theranostics continue to gain momentum

Article by Richard Zimmermann, President & Founder of the Oncidium foundation. Radiotheranostics are molecules that can safely carry radioactive isotopes inside targeted human...

In memory of Sanjiv Sam Gambhir, a leader in the development of precision oncology

Molecular imaging pioneer Sanjiv Sam Gambhir, MD, PhD, passed away on Saturday, July 18, from cancer. He was 57. From the earliest days of his...

Another milestone for the Oncidium foundation

Another milestone for the Oncidium foundation: 200 registered hospitals and counting! Thank you to all the nuclear medicine experts that registered their treatment center using...

The Oncidium foundation supports the SVIMS

In India, the Sri Venkateswara Institute of Medical Sciences (SVIMS), is a University Hospital based in Tirupati. The city is home to most famous...

SNMMI 2020 – Virtual Edition

Event: SNMMI 2020 Annual Meeting - Virtual Edition Date: 11-14 July 2020 The Oncidium foundation will be virtually attending and holding a booth. Find us under...

Atomic Nanogenerators in Targeted Alpha Therapy

Atomic in vivo nanogenerators such as actinium-225, thorium-227, and radium-223 are of increasing interest and importance in Targeted Alpha Therapy (TAT), in the treatment...

Postponing PRRT treatment during COVID 19

Postponing PRRT in Neuroendocrine tumors during COVID-19. What do you think? Check out the interesting responses of experts in the field. Read more >>

ProsTIC – The new Centre of Excellence

Congratulations Peter MacCallum Cancer Centre for the launch of The Prostate Theranostics & Imaging Centre of Excellence. ProsTIC will lead state-of-the-art research to deliver new...

Prostate Cancer Theranostics – An Overview

The implementation of theranostic approaches to characterize and personalize patient management is beginning to be realized for prostate cancer patients. This review article summarized...

EANM FOCUS MEETING – Theranostics for NET’s

Event: EANM FOCUS 3 - Molecular Imaging and Theranostics in Neuroendocrine tumours Date: Jan 30 - Feb 01, 2020 Location: Athens, Greece In-depth overview of the latest...

ARAB HEALTH 2020

Event: Arab Health 2020 Date: 27 - 30 January 2020 Location: UAE - Dubai World Trade Center

CONNECT-SE CONOSCO

5 days ago
We may be waiting for the pandemic to be over, but cancer does not wait! Don't miss out on tomorrow's launch of the #TimeToActCancer Don’t let Covid-19 stop you from tackling cancer” campaign.
@EuropeanCancer
https://t.co/LvIv7WIiKH
#BeatingCancer #earlydetection #EUCancerPlan
European Cancer Organisation @EuropeanCancer
Join the virtual launch of the #TimeToActCancer campaign 👇

'Don't let #Covid19 stop you from tackling #Cancer'

💡 New data
🗣 Resources in over 30 languages
🗓 Tuesday, 11 May @ 11:00-12:00 CEST

ℹ️ Register @ https://t.co/NfHhVM6tLZ

#BeatingCancer https://t.co/XpDtzuPXt6
1 week ago
With increasing variety of #radiopharmaceuticals for #diagnostic or #therapeutic #nuclearmedicine as valuable diagnostic or treatment option, radiobiology plays an important role in supporting optimizations incl. safety & efficacy of #radionuclidetherapies
https://t.co/dXTWBh4ZB5
2 weeks ago
Supporting our Ambassador in a project that aims to enable imaging access to all men with #prostatecancer takes on its full meaning, notably as Africa is the least developed region worldwide for PET/CT infrastructure, with #SPECT cameras outnumbering PET by 7 to 1.
#NobleRegistry https://t.co/HbyZ4vUNMU
Noble Registry @NobleRegistry
It's been 2 weeks since the launch of the #NobleRegistry. Dr. Akintunde Orunmuyi, investigator for the University College Hospital in Ibadan, Nigeria, where the first patient was dosed, looks forward to a better future with #NobodyLeftBehind for people living with #prostatecance https://t.co/QVsVsVpNMF